1 of 1
Story summary
- Insilico Medicine said rentosertib cut biological age in a Phase 2 trial of chronic lung disease patients.
- The study used six aging clocks from Insilico, Harvard and Peking University on blood samples from 42 participants.
- Four weeks after the first dose, average biological age dropped up to six years, while placebo showed little change.
- Insilico shares rose as much as 10% on Tuesday, its biggest gain since Aug. 25.
